- The Kilkenny facility is part of a €440 million investment in Ireland.
- The site will employ more than 800 people and produce FreeStyle Libre 3 sensors.
- Abbott has been in Ireland since 1946 and employs about 6,000 people across 10 sites.
- Abbott is also investing £85 million in its Witney facility in the UK.
Facility Overview
Abbott has opened a new manufacturing facility in Kilkenny, Ireland, marking a significant expansion in its global operations. This site will serve as a manufacturing center for Abbott’s diabetes care business, specifically producing FreeStyle Libre 3 sensors. The facility is expected to employ over 800 people, contributing to the local economy and enhancing Ireland's position in the healthcare manufacturing sector.
Investment and Expansion
The Kilkenny facility is part of a broader €440 million investment in Ireland, which also includes expanding Abbott's Donegal site, creating an additional 200 jobs. This investment underscores Abbott's commitment to Ireland as a strategic location for its operations. Additionally, Abbott is investing £85 million in its Witney facility in Oxfordshire, UK, to further boost its manufacturing capabilities in Europe.
Sustainability Initiatives
Designed with sustainability in mind, the Kilkenny facility is fully electric, utilizing six air-to-water heat pumps and nearly 600 solar panels. It also features rainwater collection tanks for onsite use, aligning with Abbott's environmental goals and reducing the facility's carbon footprint.
Educational Support
Abbott is also supporting local education through a $100,000 grant to The Ireland Funds, aimed at funding scholarships for three 2024 Leaving Certificate graduates from local DEIS schools. These scholarships will enable students to pursue third-level education in STEM fields, reflecting Abbott's commitment to fostering future talent in science, technology, engineering, and mathematics.
Abbott's Legacy in Ireland
Operating in Ireland since 1946, Abbott currently employs around 6,000 people across 10 sites. This long-standing presence highlights the company's ongoing investment in the region and its role in advancing healthcare solutions globally.
